CALCIUM-ANTAGONISTS AND HORMONE-RELEASE .1. EFFECTS OF VERAPAMIL ON INSULIN RELEASE IN NORMAL SUBJECTS AND PATIENTS WITH ISLET-CELL TUMOR
CALCIUM-ANTAGONISTS AND HORMONE-RELEASE .1. EFFECTS OF VERAPAMIL ON INSULIN RELEASE IN NORMAL SUBJECTS AND PATIENTS WITH ISLET-CELL TUMOR
复制标题
DOI：
10.1016/0026-0495(80)90103-1
复制
发表时间：
1980-01-01
影响因子：
9.8
通讯作者：
BARBARINO, A
中科院分区：
文献类型：
--
作者：
DEMARINIS, L;BARBARINO, A
静脉输注钙离子转运的有机拮抗剂维拉帕米可显著抑制葡萄糖、高血糖素和磺脲类药物引起的正常人血清胰岛素水平的升高。此外，促分泌剂联合维拉帕米后的血糖浓度仍显著高于单独应用促分泌剂后。维拉帕米+高血糖素给药后血糖呈规律性升高，提示维拉帕米不能抑制高血糖素诱导的肝糖原分解。两名胰岛细胞瘤患者接受维拉帕米治疗5天后，低血糖发作的严重程度和频率降低，同时“自主”胰岛素释放受到抑制。目前的结果清楚地表明，钙拮抗剂能够抑制正常受试者对适当刺激的胰岛素反应。根据目前的研究结果，钙拮抗剂和磺脲类药物的联合治疗应谨慎使用。钙拮抗剂是治疗胰岛细胞瘤所致低血糖的有效药物。
Intravenous infusion of verapamil, an organic antagonist of calcium transport into cells, produced a marked and significant inhibition of glucose-, glucagon- and sulfonylurea-induced increases in serum insulin in normal subjects. Also, blood glucose concentrations remained significantly higher after the secretagogue plus verapamil than after the secretagogue alone. Blood glucose concentrations increased regularly after verapamil + glucagon administration indicating that verapamil is not capable of inhibiting the hepatic glycogenolysis induced by glucagon. Two patients with islet-cell tumor, treated with verapamil for 5 days, experienced a decrease in the severity and frequency of hypoglycemic attacks while “autonomous” insulin release was inhibited. The present results clearly show that calcium antagonists are capable of inhibiting insulin response to appropriate stimuli in normal subjects. Therapeutic association of calcium antagonists and sulfonylureas should be used with caution in the light of the present findings. Calcium antagonists can be useful drugs in the treatment of hypoglycemia caused by islet-cell tumor.